Formycon AG (FYB.DE)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
52.30
-0.50 (-0.95%)
At close: Feb 10, 2025, 5:00 PM
undefined% (undefined)
Bid | n/a |
Market Cap | 923.85M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 4.03 |
PE Ratio (ttm) | 12.98 |
Forward PE | n/a |
Analyst | n/a |
Ask | n/a |
Volume | 3,775 |
Avg. Volume (20D) | 10,149 |
Open | 52.50 |
Previous Close | 52.80 |
Day's Range | 52.30 - 53.40 |
52-Week Range | 37.65 - 64.40 |
Beta | undefined |
About FYB.DE
Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease an...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 4, 2011
Employees 239
Stock Exchange XETRA
Ticker Symbol FYB.DE
Website https://www.formycon.com